Patents Examined by Sergio Coffa
-
Patent number: 12037416Abstract: The subject invention provides compositions and methods for alleviating pain. Specifically, the subject invention provides pharmaceutical formulations of polymers, and/or their salts, having advantageous ?-opioid receptor binding activity.Type: GrantFiled: November 19, 2018Date of Patent: July 16, 2024Assignee: CYTOGEL PHARMA, LLCInventors: Theodore E. Maione, James Hamsher, Constantine Basil Maglaris
-
Patent number: 12037374Abstract: The invention provides antibiotic BPI Fold Containing Family A Member 2 (BPIFA2) peptides, compositions comprising a BPIFA2 peptide, hydrogels comprising a BPIFA2 peptide, nanofibrillar networks comprising a BPIFA2 peptide, and tissue scaffolds comprising BPIFA2 peptides. The peptide, compositions, hydrogels nanofibrillar networks and tissue scaffolds are useful for medical therapy in an animal.Type: GrantFiled: November 16, 2020Date of Patent: July 16, 2024Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: Sven-Ulrik Gorr, Conrado Aparicio, Zhou Ye
-
Patent number: 12029779Abstract: The present invention relates to semaglutide for use in weight management.Type: GrantFiled: April 9, 2020Date of Patent: July 9, 2024Assignee: Novo Nordisk A/SInventors: Marianne Oelholm Larsen Groenning, Lars Endahl, Charlotte Giwercman Carson, Anders Bjerring Strathe, Maria Kabisch, Thomas Hansen
-
Patent number: 12024544Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.Type: GrantFiled: November 21, 2022Date of Patent: July 2, 2024Assignee: Rosalind Franklin University of Medicine and ScienceInventor: Bruce L. Riser
-
Patent number: 12018059Abstract: This invention relates to isolated polypeptides that are analogs of human amylin. The disclosed amylin analog polypeptides have beneficial physicochemical properties relative to endogenous amylin, such as longer elimination half-lives (t1/2) and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed amylin analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed amylin analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as types 1 and 2 diabetes, and providing weight loss.Type: GrantFiled: October 10, 2019Date of Patent: June 25, 2024Assignee: I2O THERAPEUTICS, INC.Inventors: William Blackwell, Ved P. Srivastava, James M. Way
-
Patent number: 12012468Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: September 27, 2022Date of Patent: June 18, 2024Assignees: MERCK SHARP & DOHME LLC, RA PHARMACEUTICALS, INC.Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Mark W. Embrey, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. Gilbert, Aurash Shahripour, Yusheng Xiong
-
Patent number: 11999804Abstract: An object of the present invention is to provide an excellent treatment agent for a lysosomal storage disease. According to the present invention, there is provided a treatment agent for a lysosomal storage disease including a cell structure which includes a plurality of biocompatible polymer blocks and a plurality of cells of at least one type and in which at least one of the polymer blocks is disposed in gaps between the plurality of cells.Type: GrantFiled: December 27, 2019Date of Patent: June 4, 2024Assignees: FUJIFILM Corporation, KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Kentaro Nakamura, Tsukasa Kitahashi, Rie Hando, Satoshi Gojo, Daisuke Kami
-
Patent number: 11992036Abstract: A method of alleviating symptoms of, or treating, pancreatic beta-cell damage in a subject includes a step of identifying a subject having pancreatic beta-cell damage. Multiple cycles of a diet protocol are administered to the subject. The diet protocol includes administering of a fasting mimicking diet and a re-feeding diet where the fasting mimicking diet is provided for a first time period and the re-feeding diet is provided for a second time period.Type: GrantFiled: January 29, 2021Date of Patent: May 28, 2024Assignee: University of Southern CaliforniaInventors: Valter D. Longo, Chia-Wei Cheng
-
Patent number: 11987647Abstract: Disclosed are cell penetrating peptides and compositions comprising such peptides that can be used to deliver agents to various cell types.Type: GrantFiled: May 9, 2019Date of Patent: May 21, 2024Assignee: Ohio State Innovation FoundationInventor: Dehua Pei
-
Patent number: 11981710Abstract: Described herein are proteins comprising an ankyrin repeat domain having an N-terminal capping module with improved properties, as well as corresponding protein libraries, pharmaceutical compositions and nucleic acids encoding such proteins. In other aspects, the disclosure relates to methods using such proteins, corresponding protein libraries or pharmaceutical compositions.Type: GrantFiled: June 28, 2022Date of Patent: May 14, 2024Assignee: Athebio AGInventors: Johannes Schilling, Patrik Forrer
-
Patent number: 11976137Abstract: The present invention relates to synthetic polypeptide compounds which bind to a class A G-protein-coupled receptor, the Apelin receptor. These compounds may act as apelin receptor antagonists. These compounds and compositions comprising them may be useful in the treatment of diseases, such as cancer.Type: GrantFiled: April 4, 2019Date of Patent: May 7, 2024Assignee: Cambridge Enterprise LimitedInventors: Anthony Peter Davenport, Robert Charles Glen, Janet Julie Maguire
-
Patent number: 11976100Abstract: The present disclosure provides methods for treating or ameliorating a myelin associated disease or a mitochondria associated disease that comprising administering to a subject in need thereof a frataxin replacement therapeutic compound, e.g., a fusion protein comprising frataxin.Type: GrantFiled: April 30, 2021Date of Patent: May 7, 2024Assignee: Larimar Therapeutics, Inc.Inventor: Joan David Bettoun
-
Patent number: 11965006Abstract: This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWW????GLLG?LLG?V??VIK?L??I (SEQ ID No. 2), LKKWWK??KGLLGGLLGKV??VIK (SEQ ID No. 12), and ?KK??KK?KG?LGGL?GK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.Type: GrantFiled: November 19, 2021Date of Patent: April 23, 2024Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Berthony Deslouches, Yuanpu Di
-
Patent number: 11957762Abstract: Disclosed herein, are recombinant polypeptides comprising one or more homologous amino acid repeats; and, non-immunogenic bioconjugates comprising recombinant polypeptides comprising one or more homologous amino acid repeats and one or more therapeutic agents. Also, disclosed herein are pharmaceutical compositions including the recombinant polypeptides; and methods of administering the recombinant polypeptides to patients for the treatment of cancer or infections.Type: GrantFiled: May 27, 2016Date of Patent: April 16, 2024Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Mingnan Chen, Hyung Jin Cho, Peng Wang, Shuyun Dong, Peng Zhao
-
Patent number: 11938166Abstract: The present invention provides compositions and formulations comprising glutathione with or without thiocyanate and methods of use thereof to treat diseases and disorders in mucosal/epithelial tissue.Type: GrantFiled: June 15, 2021Date of Patent: March 26, 2024Assignee: The University of North Carolina at Chapel HillInventors: Roland R. Arnold, David C. Henke
-
Patent number: 11932705Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.Type: GrantFiled: August 29, 2022Date of Patent: March 19, 2024Assignees: MERCK SHARP & DOHME LLC, RA PHARMACEUTICALS, INC.Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
-
Patent number: 11911436Abstract: The present disclosure provides amphiphilic peptide chaperones. Also provided are their incorporation into pharmaceutical compositions and methods of use for preventing or reducing a source of stress in cells and for the treatment of disorders including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), cataract, age-related macular degeneration (AMD), glaucoma, and retinitis pigmentosa.Type: GrantFiled: June 2, 2022Date of Patent: February 27, 2024Assignee: The Curators of the University of MissouriInventors: Santhoshkumar Puttur, Krishna Sharma, Sundararajan Mahalingam
-
Patent number: 11905337Abstract: Provided are a novel peptide, a polynucleotide encoding the peptide, an expression vector including the polynucleotide, and a pharmaceutical composition including the peptide, a quasi-drug composition including the peptide, and a health functional food composition including the peptide.Type: GrantFiled: May 5, 2022Date of Patent: February 20, 2024Assignee: HYSENSBIOInventors: Joo Hwang Park, Ji Hyun Lee
-
Patent number: 11897933Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: GrantFiled: June 11, 2021Date of Patent: February 13, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
-
Patent number: 11884745Abstract: The present invention is a method for removing lipopeptides from solutions and changing their structure from cyclic to linear. The lipopeptide capture and sequestration takes place from solutions containing water through sorption. In the case of cyclic lipopeptides, in which the peptide ring is closed by a lactone bond, sorption is additionally associated with hydrolysis reactions occurring on the surface of active carbon, leading to linearization as a result of breaking the lactone bond.Type: GrantFiled: May 30, 2019Date of Patent: January 30, 2024Assignee: INVENTIONBIO SP. Z O. O.Inventors: Hanna Faltynowicz, Marek Kulazynski, Marcin Lukaszewicz